Lauren Merendino
Director/Board Member bei ESSA PHARMA INC.
Vermögen: - $ am 31.03.2024
Profil
Lauren Merendino currently works at ESSA Pharma, Inc., as Independent Non-Executive Director from 2023 and Day One Biopharmaceuticals, Inc., as Chief Commercial Officer from 2023.
Ms. Merendino also formerly worked at Genentech, Inc., as Vice President-Neurological Rare Diseases from 2018 to 2021, Myovant Sciences, Inc., as Chief Commercial Officer, and Myovant Sciences Ltd., as Chief Commercial Officer.
Ms. Merendino received her Masters Business Admin degree from New York University and undergraduate degree from The Pennsylvania State University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ESSA PHARMA INC
-.--% | 25.03.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Lauren Merendino
| Unternehmen | Position | Beginn |
|---|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.05.2023 |
| ESSA PHARMA INC. | Director/Board Member | 06.06.2023 |
Ehemalige bekannte Positionen von Lauren Merendino
| Unternehmen | Position | Ende |
|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01.04.2021 |
Myovant Sciences, Inc.
 Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Corporate Officer/Principal | - |
| MYOVANT SCIENCES LTD. | Corporate Officer/Principal | - |
Ausbildung von Lauren Merendino
| New York University | Masters Business Admin |
| The Pennsylvania State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ESSA PHARMA INC. | Health Technology |
| DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Health Technology |
Myovant Sciences Ltd.
 Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
